載入...
A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
INTRODUCTION: iGlarLixi is a titratable, fixed-ratio combination of insulin glargine (100 units/mL) and lixisenatide (33 μg/mL). This review evaluates the overall safety and adverse event (AE) profile of iGlarLixi in patients with type 2 diabetes. METHODS: We collated patient-level data from the pha...
Na minha lista:
| 發表在: | Diabetes Ther |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer Healthcare
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6349286/ https://ncbi.nlm.nih.gov/pubmed/30539523 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-018-0547-5 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|